Cibus (CBUS) Change in Accured Expenses (2016 - 2025)
Cibus (CBUS) posted Change in Accured Expenses of $307000.0 for Q4 2025, up 106.57% sequentially from -$4.7 million in Q3 2025, and up 230.11% YoY from $93000.0 in Q4 2024.
Cibus (CBUS) Change in Accured Expenses (2016 - 2025) Analysis & Trends
Cibus has reported Change in Accured Expenses for 10 years, with the latest figure at $307000.0 in Q4 2025.
- Quarterly Change in Accured Expenses rose 230.11% year-over-year to $307000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$367000.0 (up 31.4% YoY) and the FY2025 annual result came in at -$367000.0, up 31.4% from the prior year.
- Change in Accured Expenses advanced to $307000.0 in Q4 2025 per CBUS's latest filing, from -$4.7 million in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $4.7 million in Q2 2025 and troughed at -$4.7 million in Q3 2025.
- A 5-year average of $28200.0 and a median of $65000.0 in 2022 frame the typical range for Change in Accured Expenses.
- The widest YoY moves for Change in Accured Expenses: up 2694.74% in 2023, down 578.01% in 2023.
- Over 5 years, Change in Accured Expenses stood at $238000.0 in 2021, then plunged by 115.97% to -$38000.0 in 2022, then jumped by 2694.74% to $986000.0 in 2023, then tumbled by 90.57% to $93000.0 in 2024, then surged by 230.11% to $307000.0 in 2025.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered $307000.0, -$4.7 million, and $4.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cibus | 129.72 Mn | 109.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 307,000.00 |
| Dec 31, 2025 | 307,000.00 |
| Sep 30, 2025 | -4.67 Mn |
| Sep 30, 2025 | -4.67 Mn |
| Jun 30, 2025 | 4.74 Mn |
| Jun 30, 2025 | 4.74 Mn |
| Mar 31, 2025 | -745,000.00 |
| Mar 31, 2025 | -745,000.00 |
| Dec 31, 2024 | 93,000.00 |
| Dec 31, 2024 | 93,000.00 |
| Sep 30, 2024 | -1.65 Mn |
| Sep 30, 2024 | -1.65 Mn |
| Jun 30, 2024 | 1.58 Mn |
| Jun 30, 2024 | 1.58 Mn |
| Mar 31, 2024 | -554,000.00 |
| Mar 31, 2024 | -554,000.00 |
| Dec 31, 2023 | 986,000.00 |
| Dec 31, 2023 | 986,000.00 |
| Sep 30, 2023 | -1.39 Mn |
| Sep 30, 2023 | -1.39 Mn |